Sponsor Check › Person
Related person on Form D filings · address states as listed: MN, MA, NH, NY · listed Dec 30, 2015 → Oct 20, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
2 of 50 offerings report sales commissions totalling $11,550,000; 2 report finder's fees totalling $3,593,000; 8 report proceeds to related persons totalling $13,530,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Oct 20, 2026 D/A File 021-561568 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of capital commitments of the Issuer's limited partners as specified in the Issuer's partnership agreement. | Polaris Investments AG no CRD number reported FNEX Capital, LLC BrokerCheck CRD 166316 ↗ |
| EDGAR ↗ | Jul 24, 2026 D File 021-592098 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 7, 2026 D/A File 021-509961 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 31, 2026 D/A File 021-542353 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 18, 2025 D File 021-564316 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 5, 2025 D File 021-556816 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2024 D File 021-512641 | $0 | $0 | $2,100,000 (est.) The estimate is $2,100,000 for one year of salary for all officers. | None listed on this filing |
| EDGAR ↗ | Apr 12, 2024 D File 021-510405 | $0 | $0 | $1,800,000 (est.) The estimate is $1,800,000 for one year of salary for all the officers. | None listed on this filing |
| EDGAR ↗ | Dec 29, 2023 D File 021-501189 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 7, 2023 D File 021-483559 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 21, 2023 D/A File 021-433169 | $0 (est.) | $0 (est.) | $0 | Denning & Company LLC BrokerCheck CRD 115971 ↗ |
| EDGAR ↗ | Mar 13, 2023 D File 021-475621 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 13, 2023 D File 021-475679 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 13, 2023 D File 021-470671 | $0 | $0 | $2,200,000 (est.) Amount consist of salaries payable over next 12 months to executive officers and fees payable to an affiliate of directors for certain finance, accounting and administrative services. | None listed on this filing |
| EDGAR ↗ | Dec 30, 2022 D File 021-469288 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 23, 2022 D File 021-468628 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 1, 2022 D File 021-457747 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 1, 2022 D File 021-447704 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 30, 2022 D File 021-439554 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 25, 2022 D File 021-430685 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 17, 2021 D File 021-425703 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 3, 2021 D File 021-419648 | $0 | $3,125,000 | $0 | SVB Leerink LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Jul 29, 2021 D/A File 021-407954 | $0 | $0 | $1,380,000 Amount consist of salaries payable over next [12 months] to executive officers and fees payable to an affiliate of directors for certain finance, accounting and administrative services. | None listed on this filing |
| EDGAR ↗ | Jul 1, 2021 D/A File 021-368862 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 23, 2021 D File 021-403985 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 22, 2021 D File 021-403725 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 2, 2021 D File 021-401543 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 11, 2020 D File 021-372991 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 24, 2020 D File 021-369623 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 1, 2020 D File 021-368023 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 18, 2020 D File 021-367164 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 1, 2020 D File 021-364097 | $0 | $0 | $1,380,000 Amount consist of salaries payable over next [12 months] to executive officers and fees payable to an affiliate of directors for certain finance, accounting and administrative services. | None listed on this filing |
| EDGAR ↗ | Mar 19, 2020 D File 021-363219 | $0 | $468,000 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 28, 2020 D File 021-361645 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 25, 2019 D File 021-354117 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 20, 2019 D File 021-353793 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 17, 2019 D File 021-342127 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 17, 2019 D File 021-337559 | $10,150,000 (est.) | $0 | $0 | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ Credit Suisse Securities (USA) LLC BrokerCheck CRD 816 ↗ |
| EDGAR ↗ | Jan 28, 2019 D File 021-331551 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 6, 2018 D File 021-318570 | $0 | $0 | $900,000 (est.) The issuer anticipates that it will use a portion of the proceeds of the offering to pay compensation, which is currently expected to be approximately $900,000 per year in the aggregate, for certain of the individuals named in item 3 above. | None listed on this filing |
| EDGAR ↗ | Mar 1, 2018 D File 021-306751 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 4, 2017 D File 021-300012 | $1,400,000 | $0 | $0 | Citigroup Global Markets Inc. BrokerCheck CRD 7059 ↗ Cowen and Company, LLC BrokerCheck CRD 7616 ↗ Piper Jaffray & Co. BrokerCheck CRD 665 ↗ |
| EDGAR ↗ | Jun 23, 2017 D File 021-289354 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2017 D File 021-286233 | $0 | $0 | $3,000,000 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 19, 2017 D/A File 021-266863 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 1, 2016 D/A File 021-271785 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2016 D File 021-262117 | $0 | $0 | $770,000 (est.) Ordinary course compensation for services. | None listed on this filing |
| EDGAR ↗ | Dec 30, 2015 D File 021-254201 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 28, 2015 D/A File 021-242788 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 5, 2015 D/A File 021-201235 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Polaris Partners XI, L.P. group: Polaris | Executive Officer Managing Member of the General Partner | Oct 20, 2026 | D/A | $500,000,000 similar: $155,000–$5,250,000 | $187,247,190 | 24 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | MeridianMade, Inc. group: Liontree | Director | Jul 24, 2026 | D | $20,343,840 similar: $829,831–$9,999,998 | $20,343,840 | 36 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | May 7, 2026 | D/A | $95,499,340 similar: $829,831–$9,999,998 | $95,493,537 | 46 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Mar 31, 2026 | D/A | $173,076,802 similar: $829,831–$9,999,998 | $72,177,578 | 49 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Sequelae, Inc. | Director | Nov 18, 2025 | D | $1,485,000 similar: $1,100,015–$10,001,163 | $222,750 | 2 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Polaris Partners XI, L.P. group: Polaris | Executive Officer Managing Member of the General Partner | Oct 21, 2025 | D | $500,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | QurAlis Corp | Director | Sep 5, 2025 | D | $24,921,734 similar: $1,694,259–$16,000,000 | $19,952,387 | 19 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | May 13, 2025 | D/A | $95,499,340 similar: $829,831–$9,999,998 | $95,493,537 | 46 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Mar 27, 2025 | D | $173,076,802 similar: $829,831–$9,999,998 | $72,177,578 | 49 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Sequelae, Inc. | Director | May 8, 2024 | D | $20,000,000 similar: $1,100,015–$10,001,163 | $20,000,000 | 2 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Sequelae, Inc. | Director | Apr 12, 2024 | D | $60,000,000 similar: $1,100,015–$10,001,163 | $60,000,000 | 7 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Apr 8, 2024 | D | $150,007,736 similar: $829,831–$9,999,998 | $80,046,633 | 4 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Director | Dec 29, 2023 | D | $206,055,340 similar: $2,000,000–$19,999,994 | $122,749,667 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Director | Jun 7, 2023 | D | $179,262,848 similar: $2,000,000–$19,999,994 | $20,350,715 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Partners X, L.P. group: Polaris | Executive Officer | Apr 21, 2023 | D/A | $355,000,000 similar: $155,000–$5,250,000 | $354,590,909 | 92 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Volastra Therapeutics, Inc. | Director | Mar 13, 2023 | D | $60,174,997 similar: $2,000,000–$19,999,994 | $60,174,997 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | QurAlis Corp | Director | Mar 13, 2023 | D | $88,019,211 similar: $1,694,259–$16,000,000 | $59,982,508 | 27 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Jan 13, 2023 | D | $60,000,000 similar: $829,831–$9,999,998 | $29,639,049 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Cardurion Pharmaceuticals, Inc. | Director | Dec 30, 2022 | D | $17,500,000 similar: $2,000,000–$19,999,994 | $17,500,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Amagma, Inc. | Director | Dec 23, 2022 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | QurAlis Corp | Director | Sep 1, 2022 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $5,000,000 | 19 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Amagma, Inc. | Director | Jun 1, 2022 | D | $2,275,888 similar: $2,000,000–$19,999,994 | $2,275,888 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Thirty Madison, Inc. | Director | Mar 30, 2022 | D | $111,997,233 similar: $829,831–$9,999,998 | $111,997,233 | 83 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Polaris Partners X, L.P. group: Polaris | Executive Officer | Feb 10, 2022 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Fractyl Health, Inc. | Director | Jan 25, 2022 | D | $20,075,000 similar: $500,000–$7,000,000 | $20,075,000 | 4 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | SunBird Bio, Inc. | Director | Dec 17, 2021 | D | $17,999,987 similar: $2,000,000–$19,999,994 | $17,999,987 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cardurion Pharmaceuticals, Inc. | Director | Nov 3, 2021 | D | $128,125,000 similar: $2,000,000–$19,999,994 | $46,125,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Jul 29, 2021 | D/A | $90,000,000 similar: $829,831–$9,999,998 | $62,199,472 | 63 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Jul 27, 2021 | D | $90,000,000 similar: $829,831–$9,999,998 | $60,589,470 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SunBird Bio, Inc. | Director | Jul 1, 2021 | D/A | $46,699,979 similar: $2,000,000–$19,999,994 | $46,699,979 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Director | Jun 23, 2021 | D | $65,000,000 similar: $2,000,000–$19,999,994 | $60,470,112 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Fractyl Health, Inc. | Director | Jun 22, 2021 | D | $99,999,949 similar: $829,831–$9,999,998 | $99,999,949 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Thirty Madison, Inc. | Director | Jun 2, 2021 | D | $140,999,762 similar: $829,831–$9,999,998 | $140,999,762 | 26 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Cyclerion Therapeutics, Inc. | Director | Aug 11, 2020 | D | $24,250,000 similar: $1,694,259–$16,000,000 | $24,250,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Polaris Healthcare Technology Opportunities Fund, L.P. group: Polaris | Executive Officer Managing Member of the General Partner | Jun 24, 2020 | D | $100,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | SunBird Bio, Inc. | Director | Jun 12, 2020 | D | $45,000,000 similar: $2,000,000–$19,999,994 | $26,106,974 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SQZ Biotechnologies Co | Director | Jun 1, 2020 | D | $70,203,000 similar: $2,000,000–$19,999,994 | $66,253,006 | 27 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | QurAlis Corp | Director | May 18, 2020 | D | $60,000,000 similar: $1,694,259–$16,000,000 | $33,222,703 | 25 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | ByHeart, Inc. group: Liontree | Director | Apr 1, 2020 | D | $102,069,569 similar: $829,831–$9,999,998 | $96,885,369 | 99 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Fractyl Health, Inc. | Director | Mar 19, 2020 | D | $44,750,503 similar: $829,831–$9,999,998 | $44,750,503 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Amagma, Inc. | Director | Feb 28, 2020 | D | $16,369,985 similar: $829,831–$9,999,998 | $16,369,985 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | SQZ Biotechnologies Co | Director | Nov 25, 2019 | D | Indefinite similar: $2,000,000–$19,999,994 | $71,253,215 | 48 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cardurion Pharmaceuticals, Inc. | Director | Nov 20, 2019 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Partners IX, L.P. group: Polaris | Executive Officer | Jun 17, 2019 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Cyclerion Therapeutics, Inc. | Director | Apr 17, 2019 | D | $175,000,000 similar: $1,694,259–$16,000,000 | $175,000,000 | 49 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Executive Officer, Director | Jan 28, 2019 | D | $60,903,006 similar: $2,000,000–$19,999,994 | $55,243,392 | 23 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SunBird Bio, Inc. | Director | Aug 6, 2018 | D | $30,087,333 similar: $2,000,000–$19,999,994 | $26,087,335 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Quentis Therapeutics, Inc. | Director | Mar 1, 2018 | D | $47,874,995 similar: $2,000,000–$19,999,994 | $19,674,997 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Dec 4, 2017 | D | $20,000,000 similar: $2,000,000–$14,000,000 | $20,000,000 | 1 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Suono Bio, Inc. | Director | Jun 23, 2017 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $1,300,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | May 8, 2017 | D | $50,539,341 similar: $2,000,000–$19,999,994 | $45,539,314 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Executive Officer, Director | Apr 19, 2017 | D/A | $23,082,575 similar: $2,000,000–$19,999,994 | $23,082,575 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Executive Officer, Director | Mar 7, 2017 | D/A | $20,082,575 similar: $2,000,000–$19,999,994 | $20,082,575 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Executive Officer, Director | Feb 10, 2017 | D/A | $17,082,576 similar: $2,000,000–$19,999,994 | $17,082,576 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SQZ Biotechnologies Co | Executive Officer, Director | Dec 1, 2016 | D/A | $24,061,840 similar: $2,000,000–$19,999,994 | $24,061,840 | 34 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SQZ Biotechnologies Co | Director, Executive Officer | Oct 4, 2016 | D | $15,739,913 similar: $2,000,000–$19,999,994 | $15,739,913 | 26 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Lyndra Therapeutics, Inc. | Executive Officer, Director | Jul 13, 2016 | D | $5,932,584 similar: $2,000,000–$19,999,994 | $5,932,584 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Apr 27, 2016 | D | $15,007,220 similar: $2,000,000–$19,999,994 | $15,007,220 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Dec 30, 2015 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SQZ Biotechnologies Co | Director | Jul 28, 2015 | D/A | $5,081,019 similar: $2,000,000–$19,999,994 | $5,081,019 | 24 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SQZ Biotechnologies Co | Director | Jun 30, 2015 | D | $5,011,019 similar: $2,000,000–$19,999,994 | $5,011,019 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | X4 Pharmaceuticals, Inc group: X4 Pharmaceuticals | Director | Jun 5, 2015 | D/A | $20,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (7 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Amy Schulman. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Amy Schulman appears on a new Form D, or when a court case or SEC action is matched to them. See plans →